Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces.
Animals
Antibody Affinity
/ genetics
Computational Biology
Drug Design
HEK293 Cells
Humans
Immunoglobulin Fragments
/ chemistry
Immunoglobulin Heavy Chains
/ chemistry
Immunoglobulin Light Chains
/ chemistry
Immunoglobulin Variable Region
/ chemistry
Models, Molecular
Mutagenesis, Site-Directed
Mutation
Oxidoreductases Acting on Sulfur Group Donors
/ antagonists & inhibitors
Peptide Library
Protein Engineering
/ methods
Protein Stability
Software
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Journal
PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
03
02
2019
accepted:
21
06
2019
revised:
05
09
2019
pubmed:
24
8
2019
medline:
21
1
2020
entrez:
24
8
2019
Statut:
epublish
Résumé
Antibodies developed for research and clinical applications may exhibit suboptimal stability, expressibility, or affinity. Existing optimization strategies focus on surface mutations, whereas natural affinity maturation also introduces mutations in the antibody core, simultaneously improving stability and affinity. To systematically map the mutational tolerance of an antibody variable fragment (Fv), we performed yeast display and applied deep mutational scanning to an anti-lysozyme antibody and found that many of the affinity-enhancing mutations clustered at the variable light-heavy chain interface, within the antibody core. Rosetta design combined enhancing mutations, yielding a variant with tenfold higher affinity and substantially improved stability. To make this approach broadly accessible, we developed AbLIFT, an automated web server that designs multipoint core mutations to improve contacts between specific Fv light and heavy chains (http://AbLIFT.weizmann.ac.il). We applied AbLIFT to two unrelated antibodies targeting the human antigens VEGF and QSOX1. Strikingly, the designs improved stability, affinity, and expression yields. The results provide proof-of-principle for bypassing laborious cycles of antibody engineering through automated computational affinity and stability design.
Identifiants
pubmed: 31442220
doi: 10.1371/journal.pcbi.1007207
pii: PCOMPBIOL-D-19-00192
pmc: PMC6728052
doi:
Substances chimiques
Immunoglobulin Fragments
0
Immunoglobulin Heavy Chains
0
Immunoglobulin Light Chains
0
Immunoglobulin Variable Region
0
Peptide Library
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
immunoglobulin Fv
0
Oxidoreductases Acting on Sulfur Group Donors
EC 1.8.-
QSOX1 protein, human
EC 1.8.3.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1007207Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Science. 2016 May 6;352(6286):657-8
pubmed: 27151851
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3539-44
pubmed: 14988501
MAbs. 2013 Jul-Aug;5(4):523-32
pubmed: 23765106
Structure. 1993 Oct 15;1(2):83-93
pubmed: 8069628
Protein Eng Des Sel. 2010 Sep;23(9):689-97
pubmed: 20591902
Chem Biol. 2012 Apr 20;19(4):449-55
pubmed: 22520751
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):944-949
pubmed: 28096333
MAbs. 2013 Sep-Oct;5(5):787-94
pubmed: 23883920
J Pharm Sci. 2009 Jun;98(6):1962-79
pubmed: 18855914
Nat Biotechnol. 2012 May 27;30(6):543-8
pubmed: 22634563
Nat Protoc. 2007;2(1):1-4
pubmed: 17401330
Proteins. 2015 Aug;83(8):1385-406
pubmed: 25670500
Elife. 2016 Jan 29;5:
pubmed: 26824389
J Mol Biol. 2004 Oct 22;343(3):685-701
pubmed: 15465055
Methods Enzymol. 2013;523:1-19
pubmed: 23422423
Nat Methods. 2010 Sep;7(9):741-6
pubmed: 20711194
Nature. 2012 Aug 16;488(7411):414-8
pubmed: 22801504
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8705-10
pubmed: 27436899
Molecules. 2011 May 03;16(5):3675-700
pubmed: 21540796
J Mol Biol. 2004 Jul 23;340(5):1073-93
pubmed: 15236968
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10879-84
pubmed: 22745168
Nat Biotechnol. 2007 Oct;25(10):1171-6
pubmed: 17891135
J Vis Exp. 2010 Jun 19;(40):
pubmed: 20567215
Biochem Biophys Res Commun. 2012 Nov 23;428(3):395-400
pubmed: 23103372
Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1494-9
pubmed: 22307603
Proteins. 2017 Jan;85(1):30-38
pubmed: 27717001
Anal Chem. 2017 Apr 18;89(8):4708-4715
pubmed: 28345864
J Struct Biol. 2010 Oct;172(1):34-44
pubmed: 20600952
Elife. 2016 Dec 30;5:
pubmed: 28035901
J Chem Theory Comput. 2015 Feb 10;11(2):609-22
pubmed: 25866491
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):11937-42
pubmed: 19571001
PLoS One. 2011;6(6):e20161
pubmed: 21731610
Adv Immunol. 1988;43:99-132
pubmed: 3055855
Nat Methods. 2007 Jun;4(6):466-7
pubmed: 17538626
Nat Rev Immunol. 2010 May;10(5):345-52
pubmed: 20414207
Protein Sci. 2016 Jul;25(7):1179-87
pubmed: 26821641
Sci Rep. 2017 Mar 28;7:45259
pubmed: 28349921
J Biol Chem. 2006 Mar 10;281(10):6625-31
pubmed: 16373345
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):998-1002
pubmed: 28096331
Annu Rev Biochem. 2018 Jun 20;87:105-129
pubmed: 29401000
Nat Commun. 2018 Jul 17;9(1):2780
pubmed: 30018322
J Chem Theory Comput. 2016 Dec 13;12(12):6201-6212
pubmed: 27766851
J Immunol. 2006 Jul 1;177(1):333-40
pubmed: 16785529
J Mol Biol. 2007 Nov 16;374(1):130-46
pubmed: 17916365
Mol Cell. 2018 Oct 4;72(1):178-186.e5
pubmed: 30270109
BMC Biotechnol. 2008 Dec 04;8:91
pubmed: 19055817
AAPS J. 2006 Aug 04;8(3):E501-7
pubmed: 17025268
J Mol Biol. 2013 Nov 15;425(22):4366-78
pubmed: 23867277
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10701-5
pubmed: 10984501
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13722-7
pubmed: 16954202
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Science. 1992 Feb 21;255(5047):959-65
pubmed: 1546293
Science. 2016 May 6;352(6286):680-7
pubmed: 27151862
Nat Biotechnol. 2004 Sep;22(9):1161-5
pubmed: 15300256
Nat Protoc. 2006;1(2):755-68
pubmed: 17406305
Mol Cell. 2016 Jul 21;63(2):337-346
pubmed: 27425410
J Pharm Sci. 2015 Jun;104(6):1885-1898
pubmed: 25821140
Nat Commun. 2018 Dec 11;9(1):5286
pubmed: 30538236
Nat Methods. 2014 Aug;11(8):801-7
pubmed: 25075907
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E486-E495
pubmed: 28057863
Proteins. 2014 Aug;82(8):1553-62
pubmed: 24668560
MAbs. 2015;7(3):505-15
pubmed: 25759214
J Mol Biol. 1994 Nov 4;243(4):767-81
pubmed: 7966295
AAPS J. 2006 Sep 15;8(3):E572-9
pubmed: 17025275
Oncogene. 2009 Sep 17;28(37):3307-19
pubmed: 19597465
Free Radic Biol Med. 2014 Apr;69:129-35
pubmed: 24468475
Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10900-10905
pubmed: 28973872
Proteins. 2011 Mar;79(3):830-8
pubmed: 21287615
Bioinformatics. 2019 May 1;35(9):1591-1593
pubmed: 30951584
FEBS J. 2011 Aug;278(16):2858-66
pubmed: 21651726